279 related articles for article (PubMed ID: 20216310)
1. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery.
Brown JM; Rudel LL
Curr Opin Lipidol; 2010 Jun; 21(3):192-7. PubMed ID: 20216310
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
Uto Y
Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
[TBL] [Abstract][Full Text] [Related]
3. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
[TBL] [Abstract][Full Text] [Related]
4. Probing the role of stearoyl-CoA desaturase-1 in hepatic insulin resistance.
Flowers MT; Miyazaki M; Liu X; Ntambi JM
J Clin Invest; 2006 Jun; 116(6):1478-81. PubMed ID: 16741573
[TBL] [Abstract][Full Text] [Related]
5. Stearoyl-CoA Desaturase-1 Protects Cells against Lipotoxicity-Mediated Apoptosis in Proximal Tubular Cells.
Iwai T; Kume S; Chin-Kanasaki M; Kuwagata S; Araki H; Takeda N; Sugaya T; Uzu T; Maegawa H; Araki SI
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834856
[TBL] [Abstract][Full Text] [Related]
6. Role of stearoyl-CoA desaturases in obesity and the metabolic syndrome.
Popeijus HE; Saris WH; Mensink RP
Int J Obes (Lond); 2008 Jul; 32(7):1076-82. PubMed ID: 18427563
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
[TBL] [Abstract][Full Text] [Related]
8. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
Dobrzyn A; Ntambi JM
Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis.
Brown JM; Chung S; Sawyer JK; Degirolamo C; Alger HM; Nguyen TM; Zhu X; Duong MN; Brown AL; Lord C; Shah R; Davis MA; Kelley K; Wilson MD; Madenspacher J; Fessler MB; Parks JS; Rudel LL
Arterioscler Thromb Vasc Biol; 2010 Jan; 30(1):24-30. PubMed ID: 19834103
[TBL] [Abstract][Full Text] [Related]
11. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
[TBL] [Abstract][Full Text] [Related]
12. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase.
Li ZZ; Berk M; McIntyre TM; Feldstein AE
J Biol Chem; 2009 Feb; 284(9):5637-44. PubMed ID: 19119140
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
Liu G
Curr Top Med Chem; 2010; 10(4):419-33. PubMed ID: 20180759
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis.
Brown JM; Chung S; Sawyer JK; Degirolamo C; Alger HM; Nguyen T; Zhu X; Duong MN; Wibley AL; Shah R; Davis MA; Kelley K; Wilson MD; Kent C; Parks JS; Rudel LL
Circulation; 2008 Sep; 118(14):1467-75. PubMed ID: 18794388
[TBL] [Abstract][Full Text] [Related]
15. Stearoyl-CoA desaturase-1 (SCD1) augments saturated fatty acid-induced lipid accumulation and inhibits apoptosis in cardiac myocytes.
Matsui H; Yokoyama T; Sekiguchi K; Iijima D; Sunaga H; Maniwa M; Ueno M; Iso T; Arai M; Kurabayashi M
PLoS One; 2012; 7(3):e33283. PubMed ID: 22413010
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
Dillon R; Greig MJ; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
[TBL] [Abstract][Full Text] [Related]
17. SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors.
Sun Q; Xing X; Wang H; Wan K; Fan R; Liu C; Wang Y; Wu W; Wang Y; Wang R
Biomed Pharmacother; 2024 Jan; 170():115586. PubMed ID: 38042113
[TBL] [Abstract][Full Text] [Related]
18. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
Liu G
Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
[TBL] [Abstract][Full Text] [Related]
19. Recent insights into stearoyl-CoA desaturase-1.
Ntambi JM; Miyazaki M
Curr Opin Lipidol; 2003 Jun; 14(3):255-61. PubMed ID: 12840656
[TBL] [Abstract][Full Text] [Related]
20. Loss of Stearoyl-CoA Desaturase-1 Activity Induced Leptin Resistance in Neuronal Cells.
Thon M; Hosoi T; Chea C; Ozawa K
Biol Pharm Bull; 2017; 40(8):1161-1164. PubMed ID: 28768997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
